date:Oct 25, 2018
za included diarrhea and bronchitis.
Xofluza was granted Priority Review under which the FDAs goal is to take action on an application within an expedited time frame where the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition.
The FDA granted approval of Xofluza to Shionogi Co., Ltd.